Slide 1: A profitable and growing market leader in nuclear medical imaging and lung healthcare
For personal use only Cyclopharm Limited A profitable and growing market leader in nuclear medical imaging and lung healthcare 1H2017 Results Investor Presentation 28 August 2017 1
Slide 2: 1H2017 Results Highlights
1H2017 Results Highlights For personal use only • Group Sales Revenue $6.06 million • Gross Margin $5.00 million • Net Loss After Tax ($1.43) million • Interim Dividend 0.5 cents per share • Underlying Technegas EBITDA1 $861,000 • FDA Trial expenses ($1.58) million • Strong balance sheet $10.62 mill
Slide 3: 1H2017 Operating Highlights
1H2017 Operating Highlights For personal use only Technegas continuing to perform well – Volume of Technegas generators sold increased 7% vs pcp. Unit sales of PAS, excluding the French and Chinese markets, increased 6% vs pcp. Ultralute on track for 2H sales – First commercial batch of Cyclopha
Slide 4: 1H2017 Underlying Performance
Group 1H2017 Underlying Performance For personal use only During the half year, CYC continued to implement Solid Underlying Financial Results its strategic priorities, which are to: 1. Grow the core business, based on expanding Half Year ended 30 June 2017 2016 Technegas sales in existing markets; (
Slide 5: 1H2017 Balance Sheet
Group 1H2017 Balance Sheet For personal use only Financial Foundation to Leverage Growth Strategy Debt free & $10.6m cash on hand – provides balance sheet and funding 30 June 31 Dec flexibility ($000’s) 2017 2016 Funding used toward USFDA clinical trial Cash 10,620 4,591 Other current assets 5,7
Slide 6: Cash Position
Cash Position For personal use only Solid Cash Generation & Funded for Growth Successful Capital Raising ($000’s) HY 2017 FY 2016 Operating Activities (189) 655 Completed a fully-underwritten Investing Activities (546) (2,221) Entitlement Offer that raised Financing Activities 6,311 (754) $6.59 mi
Slide 7: Company Overview
For personal use only Company Overview 7
Slide 8: Company Overview
Company Overview For personal use only Cyclopharm Limited (CYC) is a leading nuclear pharmaceuticals company • A world leader in functional lung ventilation imaging technology with recurring consumables and capital equipment revenue streams • A profitable and growing company with a history of divide
Slide 9: Cyclopharm's leading product is the Technegas technology system
Company Overview For personal use only Cyclopharm’s leading product is the Technegas technology system The Technegas proprietary technology provides high quality diagnostic functional lung imaging. Predominantly used to diagnosis the presence of blood clots in the lung otherwise known as Pulmona
Slide 10: Proven Market Adoption
Proven Market Adoption For personal use only Technegas is a substantially de-risked commercial proposition with significant upside in the US market Total global sales of $77m since 2010 Technegas currently sold in 56 countries Over 210,000 patient procedures in 2016 Over 3,700,000 patient pr
Slide 11: FDA Trial and US Commercialisation
For personal use only FDA Trial and US Commercialisation 11
Slide 12: US Market Opportunity
US Market Opportunity For personal use only The USA represents the single largest market for Technegas with half of the world’s nuclear medicine departments Target market for Technegas in the USA equates to ~480,000 patient procedures of the total 600,000 procedures conducted p.a.in that market
Slide 13: Technegas FDA Clinical Trial Process and Design
Technegas FDA Clinical Trial Process and Design For personal use only Study Specifics: • Non-inferiority structural ventilation study comparing Xe133 vs. Technegas • Pathway to approval requires a two part study CYC 010 – Establishes the Inter & Intra reader variability for Xe133 – Completed CYC
Slide 14: Technegas – The Canadian Case Study
Technegas – The Canadian Case Study For personal use only Canada is Cyclopharm’s largest single country market The Generator and Consumable Relationship 50,000 140 • Market leader for diagnosing PE Technegas Growth ‐ Canada 45,000 • 13 consecutive years of PAS growth 120 Active Generators 40,000 Pat
Slide 15: Indication expansion – Australian Initiative
Technegas Indication expansion – Australian Initiative For personal use only • Partnership with the University of Newcastle, John Hunter Hospital and Hunter Medical Research Institute • Targeting Clinical Applications in COPD Patients • Clinical Hypothesis: Small airway dysfunction assessed using Te
Slide 16: 2017 Strategic Priorities and Outlook
2017 Strategic Priorities and Outlook For personal use only Strategic Goals & Guidance Activity Timeframe United States • Commence patient recruitment Q3 2017 FDA Approval • Complete 10th clinical site installation Q4 2017 • Complete Technegas particulate study 2H 2017 • Submit preliminary 40 patien
Slide 17: Appendix
For personal use only Appendix Technegas UltraluteTM MMI Disclaimer 17
Slide 18: What is Technegas?
What is Technegas? For personal use only Technegas is the world leader in functional lung Technegas is a System ventilation imaging. In order to deliver the best clinical • Technegas is a structured ultra-fine dispersion of radioactive outcomes, Technegas requires the gas like substance which is inh
Slide 19: Advantages of Technegas
Advantages of Technegas For personal use only Technegas provides clinically superior outcomes to its Competitive Nuclear Medicine Products competitors Better clinical results at a fraction of the high radiation doses Product Comparison to Technegas used in CTPA (angiograms) No contraindications
Slide 20: FDA Approved Trial Design
FDA Approved Trial Design For personal use only De-risked clinical trial strategy - In order to mitigate regulatory risk the Company adopted the FDA Special Protocol Assessment (SPA) pathway for its US clinical trial FDA approved trial design - The SPA pathway provided the Company with the oppor
Slide 21: Pathway to US commercialisation
Pathway to US commercialisation For personal use only Target preliminary study completion Q1 2018 - During Q1 2018 the Company aims to conclude a preliminary study of 40 patients and receive feedback from the FDA. Target FDA Trial completion Q3 2018 - Assuming positive feedback from the prelimin
Slide 22: Ultralute
UltraluteTM For personal use only Innovative, first-in-class, disruptive, proprietary technology used to improve radiopharmaceutical manufacturing efficiency and deliver health care cost effectiveness Technical Features • Extension of Generator life – the Ultralute will extend the effective use of a
Slide 23: Macquarie Medical Imaging
Macquarie Medical Imaging For personal use only • Joint venture with: • 50% Alfred Health Solutions CT MRI PET • 30% Macquarie University • 20% Cyclopharm • Comprehensive suite of imaging modalities • State of the art research platform • Growth and profitability linked to ramp-up Cardiac CT Ultra‐so
Slide 24: Disclaimer
For personal use only Disclaimer Corporate Head Office Certain views expressed here contain information derived from publicly available sources that have not Cyclopharm Limited been independently verified. Unit 4, 1 The Crescent Kingsgrove NSW 2208 Australia The presentation include certain statemen